StockData
Kalaris Therapeutics, Inc. logo

Kalaris Therapeutics, Inc. (KLRS) stock

KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.43−0.03 (-2.05%)

Close on Nov 17, 2026Market cap $34.04MP/E –Yield –

Kalaris Therapeutics cash

Cash and short-term investments held at the end of each period.

Kalaris Therapeutics's cash was $93.50M at Jun 30, 2026. For fiscal 2025 it was $118.00M, down 0.3% from the year before. The highest annual figure on record is $356.32M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$118.00M-0.3%
FY2024Dec 31, 2024$118.30M-35.7%
FY2023Dec 31, 2023$183.90M-21.3%
FY2022Dec 31, 2022$233.80M-5.8%
FY2021Dec 31, 2021$248.12M-30.4%
FY2020Dec 31, 2020$356.32M+182.6%
FY2019Dec 31, 2019$126.08M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$93.50M+5.7%
Q1 FY2026Mar 31, 2026$104.90M+3.9%
Q4 FY2025Dec 31, 2025$118.00M-0.3%
Q3 FY2025Sep 30, 2025$77.00K-99.9%
Q2 FY2025Jun 30, 2025$88.43M-31.8%
Q1 FY2025Mar 31, 2025$100.97M-28.1%
Q4 FY2024Dec 31, 2024$118.30M-35.7%
Q3 FY2024Sep 30, 2024$121.90M-42.9%
Q2 FY2024Jun 30, 2024$129.60M-47.4%
Q1 FY2024Mar 31, 2024$140.50M-30.7%
Q4 FY2023Dec 31, 2023$183.90M-21.3%
Q3 FY2023Sep 30, 2023$213.30M-19.2%
Q2 FY2023Jun 30, 2023$246.50M+42.7%
Q1 FY2023Mar 31, 2023$202.60M+0.6%
Q4 FY2022Dec 31, 2022$233.80M-5.8%
Q3 FY2022Sep 30, 2022$264.10M-4.3%
Q2 FY2022Jun 30, 2022$172.70M-44.9%
Q1 FY2022Mar 31, 2022$201.40M-40.2%
Q4 FY2021Dec 31, 2021$248.12M-30.4%
Q3 FY2021Sep 30, 2021$275.84M-27.1%
Q2 FY2021Jun 30, 2021$313.34M+199.8%
Q1 FY2021Mar 31, 2021$336.99M+0.0%
Q4 FY2020Dec 31, 2020$356.32M+182.6%
Q3 FY2020Sep 30, 2020$378.50M–
Q2 FY2020Jun 30, 2020$104.50M–
Q1 FY2020Mar 31, 2020$336.90M–
Q4 FY2019Dec 31, 2019$126.08M–

More Kalaris Therapeutics figures

See a number that looks wrong?